IFPMA Issues: Counterfeit Medicines
Counterfeit Medicines
Position
Trade in counterfeit drugs is widespread and affects both developing and developed countries. All medicines are subject to counterfeiting, both branded and generic.
Counterfeit drugs are found under different forms, including:
- Products with the correct ingredients (but often with incorrect quantities of active ingredients, or time-expired active ingredients, creating an increased risk of drug resistance. The product may also have been relabelled, which can lead to allergic reactions and harmful interactions with other drugs);
- Products with the wrong ingredients (possibly toxic and therefore directly harmful to patients);
- Products without active ingredient (leaving patients at risk as their disease is left without treatment)
It is virtually impossible to tell the difference between real and fake medicines. Taking for granted that the drugs can be trusted, patients, doctors and other medical staff often do not even suspect that there is anything wrong with their medicines. However, not only is it in most cases hard to detect suspicious products, but there is also a lack of public awareness about counterfeit drugs and their seemingly uncontrolled presence on the market. As a consequence, medicines that do not work or cause unusual side-effects are rarely even reported, since symptoms (including deaths) are usually attributed to the disease. From a judicial perspective, prosecution is complicated by the fact that the evidence of counterfeiting is consumed.
Because the public health risk of counterfeit medicines recognizes no national boundaries, companies have created the Pharmaceutical Security Institute (PSI) and developed global security strategies to ensure public safety and product integrity. The pharmaceutical industry works closely with law enforcement and regulatory agencies in both developed and developing countries to implement a multilayered security strategy focused on both prevention and enforcement. The IFPMA’s Director General serves as President of the PSI.
Read the rest of this article on counterfeit medicines.
